Multiple Myeloma Awareness Month: When the Doctor Becomes the Caregiver

Read More

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

Blank et al.
Nature Medicine
November 2018
Authors and Affiliates
Blank CU1,2, Rozeman EA3,4, Fanchi LF4, Sikorska K5, van de Wiel B6, Kvistborg P4, Krijgsman O4, van den Braber M4, Philips D4, Broeks A6, van Thienen JV3, Mallo HA3, Adriaansz S3, Ter Meulen S7, Pronk LM5, Grijpink-Ongering LG5, Bruining A8, Gittelman RM9, Warren S10, van Tinteren H5, Peeper DS4, Haanen JBAG3,4, van Akkooi ACJ7, Schumacher TN11. 1 Medical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands. c.blank@nki.nl. 2 Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands. c.blank@nki.nl. 3 Medical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands. 4 Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands. 5 Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands. 6 Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands. 7 Surgical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands. 8 Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands. 9 Adaptive Biotechnologies, Seattle, WA, USA. 10 NanoString Technologies, Inc., Seattle, WA, USA. 11 Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands. t.schumacher@nki.nl.